Yansu Chen1,2, Yefei Huang1,2, Liwen Zhu1, Minjuan Chen1, Yulin Huang1, Jianbing Zhang3, Song He3, Aiping Li1, Rui Chen4, Jianwei Zhou5. 1. Department of Molecular Cell Biology and Toxicology, Cancer Center, School of Public Health, Nanjing Medical University, 101 Longmian Ave, Nanjing, 211166, People's Republic of China. 2. School of Public Health, Xuzhou Medical College, 209 Tongshan Road, Xuzhou, 221002, People's Republic of China. 3. Department of Pathology, Nantong Cancer Hospital, 30 North Tongyang Road, Pingchao, Nantong, 226361, Jiangsu Province, People's Republic of China. 4. Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, People's Republic of China. 101011816@seu.edu.cn. 5. Department of Molecular Cell Biology and Toxicology, Cancer Center, School of Public Health, Nanjing Medical University, 101 Longmian Ave, Nanjing, 211166, People's Republic of China. drjwzhou@126.com.
Abstract
PURPOSE: To investigate the potential role of SOX2 in gastric cancer (GC) metastasis. METHODS: The SOX2 expression was detected using immunohistochemistry on a GC tissue microarray. The correlations of SOX2 expression with clinicopathological factors and 5-year survival were evaluated. To test the role of SOX2 in inhibiting GC metastasis, the cell transwell assay was performed. Real-time PCR and Western blot were used to explore the possible mechanism that SOX2 inhibits GC metastasis. RESULTS: In the present study, SOX2 expression was downregulated in GC tissues when compared to matching normal tissues. Moreover, patients with high SOX2 expression in cancerous tissues had less lymph node metastasis and better treatment outcome. At the subcellular level, SOX2 inhibited the GC cell migration and invasion by upregulating p21 expression. Moreover, SOX2 was determined to associate with the nuclear p21 expression. GC patients with high SOX2 and nuclear p21 expression had synergistically less lymph node metastasis and the better overall survival. CONCLUSION: Our results suggest that SOX2 is a promising and favorable metastatic biomarker for GC.
PURPOSE: To investigate the potential role of SOX2 in gastric cancer (GC) metastasis. METHODS: The SOX2 expression was detected using immunohistochemistry on a GC tissue microarray. The correlations of SOX2 expression with clinicopathological factors and 5-year survival were evaluated. To test the role of SOX2 in inhibiting GC metastasis, the cell transwell assay was performed. Real-time PCR and Western blot were used to explore the possible mechanism that SOX2 inhibits GC metastasis. RESULTS: In the present study, SOX2 expression was downregulated in GC tissues when compared to matching normal tissues. Moreover, patients with high SOX2 expression in cancerous tissues had less lymph node metastasis and better treatment outcome. At the subcellular level, SOX2 inhibited the GC cell migration and invasion by upregulating p21 expression. Moreover, SOX2 was determined to associate with the nuclear p21 expression. GC patients with high SOX2 and nuclear p21 expression had synergistically less lymph node metastasis and the better overall survival. CONCLUSION: Our results suggest that SOX2 is a promising and favorable metastatic biomarker for GC.
Authors: O Leis; A Eguiara; E Lopez-Arribillaga; M J Alberdi; S Hernandez-Garcia; K Elorriaga; A Pandiella; R Rezola; A G Martin Journal: Oncogene Date: 2011-08-08 Impact factor: 9.867
Authors: Katharina Hütz; Raquel Mejías-Luque; Katarina Farsakova; Manfred Ogris; Stefan Krebs; Martina Anton; Michael Vieth; Ulrich Schüller; Marlon R Schneider; Helmut Blum; Ernst Wagner; Andreas Jung; Markus Gerhard Journal: Carcinogenesis Date: 2013-12-09 Impact factor: 4.944
Authors: Ida V Lundberg; Anna Löfgren Burström; Sofia Edin; Vincy Eklöf; Åke Öberg; Roger Stenling; Richard Palmqvist; Maria L Wikberg Journal: PLoS One Date: 2014-07-10 Impact factor: 3.240
Authors: F J C Ten Kate; S H van Olphen; M J Bruno; B P L Wijnhoven; J J B van Lanschot; L H J Looijenga; R C Fitzgerald; K Biermann Journal: Br J Surg Date: 2017-07-10 Impact factor: 6.939